A University of Nottingham expert has been awarded -80,000 by two national charities to study the impact of gluten intolerance on patients in the UK.
Dr Joe West will be investigating the number of people diagnosed every year with coeliac disease and the associated skin condition dermatitis herpetiformis (DH) and the health consequences for those patients with the illnesses.
Dr West, a Clinical Associate Professor and Reader in Epidemiology in the University's School of Community Health Sciences, said: "This funding will support research into a condition which affects a large number of people in the UK, many of whom will not have yet been diagnosed with coeliac disease. To enable us to fully understand the disease we need to first establish the real extent of coeliac disease in the UK today and its associated conditions and this study will hopefully lead to further improvements in the way in which patients are diagnosed and cared for through the NHS."
One in 100 people in the UK have coeliac disease, an autoimmune disease caused by intolerance to gluten, a protein found in wheat, barley and rye. There is no cure and no medication - the only treatment is a life-long, strict gluten-free diet.
It is estimated that currently only 10 to 15 per cent of those with the condition have been clinically diagnosed. As there is no official register by the NHS of diagnosed patients it is difficult to know exactly the impact that the disease is having on the UK population.
Dr West's research has been funded by Coeliac UK, the national charity for people with coeliac disease, along with Core, the UK national charity that funds research into diseases of the gut, liver and pancreas.
Starting in 2013, the study will use newly available data from anonymous patient records to investigate whether diagnosis is affected by where patients live and how affluent they are and how likely they are to be misdiagnosed with other conditions such as irritable bowel syndrome.
The research will also look at possible genetic connections such as whether a patient's chance of developing coeliac disease and DH is increased if their mother is affected by the illnesses.
In addition, it will also look at the risk posed by pneumococcal disease to coeliac sufferers - in whom the spleen, which would normally offer some protection against the disease, does not function very well - and how many patients are vaccinated against pneumococcus.
The study will be a large-scale research project looking at around 10,000 people with coeliac disease and 150,000 with irritable bowel and the results will contribute significantly to the future diagnosis and healthcare for coeliac disease in the UK and worldwide.
Sarah Sleet, Chief Executive of Coeliac UK said: "We know coeliac disease is under diagnosed but we don't know exactly how big the gap is. With an average diagnosis period of 13 years, people are enduring many years of symptoms which will impact on NHS resources.